Regional gastrointestinal delivery of remogliflozin etabonate in humans
- 7 January 2013
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 34 (2) , 79-86
Abstract
Remogliflozin etabonate (RE) is the prodrug of remogliflozin (R), an inhibitor of renal glucose transport designed to reduce blood glucose concentrations for the treatment of type 2 diabetes. This open‐label, randomized, single‐dose, four‐way crossover study, (with one add‐on arm) in eight healthy men evaluated the regional gastrointestinal absorption of RE, the systemic appearance of the active entity R, and an active metabolite, GSK279782. The InteliSite® Companion Capsule was used to administer a single dose of RE 100 mg to the mid‐small intestine or cecum/colon. Oral administration of the IR tablet of RE showed similar bioavailability of R compared with small intestine delivery with both suspension and solution. The lowest bioavailability of remogliflozin was found with large intestine delivery and therefore not a suitable region for prodrug delivery. Although both lower permeability and decreased ester hydrolysis of remogliflozin etabonate in the colon can explain reduced plasma exposures of remogliflozin, the data suggest relatively limited remogliflozin etabonate hydrolysis in the colon and provides evidence for a diminishing gradient of esterase activity from small to large intestine. Copyright © 2012 John Wiley & Sons, Ltd.Keywords
This publication has 8 references indexed in Scilit:
- Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction StudiesDrug Metabolism and Disposition, 2012
- Remogliflozin etabonate, a selective inhibitor of the sodium‐dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patientsDiabetes, Obesity and Metabolism, 2011
- The Role of Intestinal Carboxylesterase in the Oral Absorption of ProdrugsCurrent Drug Metabolism, 2010
- The use of the InteliSite® Companion device to deliver mucoadhesive polymers to the dog colonEuropean Journal of Pharmaceutical Sciences, 2009
- Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent ModelsThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Species-dependent and site-specific intestinal metabolism of ester prodrugsInternational Journal of Pharmaceutics, 2000
- Evaluation of the Feasibility and Use of a Prototype Remote Drug Delivery Capsule (RDDC) for Non-Invasive Regional Drug Absorption Studies in the GI Tract of Man and Beagle DogPharmaceutical Research, 1999
- Molecular Cloning and Characterization of a Novel Putative Carboxylesterase, Present in Human Intestine and LiverBiochemical and Biophysical Research Communications, 1997